Evidence map›Paper›PMID 27335011›Full record

ArticleWorld journal of surgical oncology2016

Evaluation of the tracing effect of carbon nanoparticle and carbon nanoparticle-epirubicin suspension in axillary lymph node dissection for breast cancer treatment.

Junze Du, Yongsong Zhang, Jia Ming, Jing Liu, Ling Zhong, Quankun Liang, Linjun Fan, Jun Jiang

Open access · goldAbstract readComparative Study
In one paragraph

Article in World journal of surgical oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
0.9field-weighted citation impact, top 26% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 23 citations in OpenAlex.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Observational
  11. Review
  12. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 1 country.

Junze DuBreast Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
Yongsong ZhangBreast Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
Jia MingThree Glands Surgery, the Second Affiliated Hospital, Chongqing Medical University, Chongqing, 400010, China.
Jing LiuBreast Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
Ling ZhongBreast Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
Quankun LiangBreast Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China.
Linjun FanBreast Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. flj212@medmail.com.cn.
Jun JiangBreast Surgery, Southwest Hospital, Third Military Medical University, Chongqing, 400038, China. jcbd@medmail.com.cn.
Army Medical University · CNSouthwest Hospital · CNSecond Affiliated Hospital of Chongqing Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCarbon nanoparticle suspension, using smooth carbon particles at a diameter of 21 nm added with suspending agents, is a stable suspension of carbon pellets of 150 nm in diameter. It is obviously inclined to the lymphatic system. There were some studies reporting that carbon nanoparticles are considered as superior tracers for sentinel lymph nodes because of their stability and operational feasibility. However, there were few study concerns about the potential treatment effect including tracing and local chemotherapeutic effect of carbon nanoparticle-epirubicin suspension on breast cancer with axillary metastasis.

methodsIn the current study, a randomized controlled analysis was performed to investigate the potential treatment effect of carbon nanoparticle-epirubicin suspension on breast cancer with axillary metastasis. A total of 90 breast cancer patients were randomly divided into three equal groups: control, tracer, and drug-load groups. The control group patients did not receive any lymphatic tracers, the tracer group patients were subcutaneously injected with 1 ml carbon nanoparticle suspension, and the drug-load group patients were injected with 3 ml carbon nanoparticle-epirubicin suspension at four separate sites around the areola 24 h before surgery. Modified radical mastectomy, endoscopic subcutaneous mammary resection plus axillary lymph node dissection, and immediate reconstruction with implants or breast-conserving surgery were performed.

resultsThe mean number of the dissected lymph nodes per patient was significantly higher in the tracer (21.3 ± 6.1) and drug-load (19.5 ± 3.7) groups than in the control group (16.7 ± 3.4) (P < 0.05). Most lymph nodes in the former two groups were stained black (75.7 and 73.3 %, respectively), but with no significant difference between the groups. Most metastatic lymph nodes were also stained black in the tracer group (68.6 %) and drug-load group (78.1 %) and with no significant difference between the groups (P = 0.198). Microscopic examination revealed that the carbon nanoparticles were localized around or among the cancer cell masses and residues of necrotized cancer cells surrounded by fibroblastic proliferation could be found within the stained lymph nodes in the drug-load group.

conclusionsThe majority of axillary lymph nodes were stained black by the suspension of carbon nanoparticles, which helped identify the lymph nodes from the surrounding tissues and avoided aggressive axillary treatment. Thus, a combination therapy of carbon nanoparticles with epirubicin could play an important role in lymphatic chemotherapy without affecting tracing.

trial registrationChiCTRTRC13003419.

Indexed as

Adenocarcinoma, MucinousAntibiotics, AntineoplasticBreast NeoplasmsCarcinoma, Ductal, BreastCarcinoma, MedullaryCase-Control StudiesCharcoalCombined Modality TherapyEpirubicinFemaleFollow-Up StudiesHumansLymphatic MetastasisLymph Node ExcisionMiddle AgedNanoparticlesAntibiotics, AntineoplasticCharcoalEpirubicinAxillary lymph node dissectionBreast neoplasmsCarbon nanoparticlesEpirubicin

Identifiers

PMID27335011
PMCPMC4918110
OpenAlexW2464304197

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.